OTR Acquisition Corp. Shares Halted On Circuit Breaker
$OTRA
OTR Acquisition Corp. Shares Halted On Circuit Breaker
Save time and jump to the most important pieces.
SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)
SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)
SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)
15-12B - OTR Acquisition Corp. (0001821318) (Filer)
8-K - OTR Acquisition Corp. (0001821318) (Filer)
25-NSE - OTR Acquisition Corp. (0001821318) (Subject)
4 - OTR Acquisition Corp. (0001821318) (Issuer)
4 - OTR Acquisition Corp. (0001821318) (Issuer)
4 - OTR Acquisition Corp. (0001821318) (Issuer)
– Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" – Comera Life Sciences Holdings, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))) (referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC). Comera Life Sciences Holdings, Inc., the resulting comb
Comera Life Sciences, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas. Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner's currently marketed medicine. "Our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma c
Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference & Expo, being held May 2-6, 2022, in-person. Dr. Mahoney will discuss Comera's lead, patented caffeine-based excipient, which significantly reduced the viscosity of prominent monoclonal antibodies without affecting their stability or biologic activity in a recent peer-reviewed study.1 The presentation details are as follows: Title: Viscosity Reducing Excipients for Highly Concentrated Antibody Formulations Time: May 4, 202
Gainers NeuroMetrix, Inc. (NASDAQ:NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia. VivoPower International PLC (NASDAQ:VVPR) gained 46.3% to close at $1.58. NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) surged 29.6% to close at $0.7905. The FDA recently reviewed NeuroOne Medical Technologies appeal for 510(k) clearance for its Evo sEEG Electrode for less than 30-day use. BIT Mining Limited (NYSE:BTCM) rose 28.1% to settle at $2.10. Pop Culture Group Co., Ltd (NASDAQ:CPOP) gained 27.6% to close at $1.11.
Gainers NeuroMetrix, Inc. (NASDAQ:NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia. Grab Holdings Limited (NASDAQ:GRAB) gained 26.1% to $3.1902 after reporting Q1 results. SIGA Technologies, Inc. (NASDAQ:SIGA) shares gained 19.9% to $8.86 after the company announced the FDA approved the intravenous formulation of TPOXX for the treatment of smallpox. Zealand Pharma A/S (NASDAQ:ZEAL) jumped 17.3% to $13.73 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenital hyperinsulin
Gainers Bright Green Corp. (NASDAQ:BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to list on a major U.S. stock exchange. Decisionpoint Systems, Inc. (NYSE:DPSI) shares climbed 70.9% to close at $8.15 on Wednesday. DecisionPoint Systems recently reported first-quarter FY22 revenue growth of 22.7% year-on-year to $19.7 million. Troika Media Group, Inc. (NASDAQ:TRKA) gained 52.1% to settle at $0.5780. Armstrong Flooring, Inc. (NYSE:AFI) climbed 46% to settle at $0.43 after receiving approval for additional financing. Magenta Therapeutics, Inc. (NASDAQ:MGTA) surged 32.2% to c